ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0465

The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists

Mehret Birru Talabi1, Bonnie Bermas2, Irene Blanco3, Ashira Blazer4, Megan Clowse5, Cuoghi Edens6, Leslie Pierce7, Catherine Wright1 and Rosalind Ramsey-Goldman3, 1University of Pittsburgh, Pittsburgh, PA, 2UT Southwestern, Dallas, TX, 3Northwestern University, Chicago, IL, 4Hospital for Special Surgery, New York, NY, 5Duke University, Chapel Hill, NC, 6University of Chicago, Chicago, IL, 7University of Pittsburgh, Raleigh, NC

Meeting: ACR Convergence 2023

Keywords: Access to care, Health policy, Health Services Research, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In June 2022, the U.S. Supreme Court’s decision in Dobbs v. Jackson Women’s Health removed the federal constitutional right to abortion, returning abortion policy to individual states. Approximately one-third of states have since banned or planned to greatly restrict abortion access. We distributed a confidential online survey to a sample of U.S.-based rheumatologists to learn how the Dobbs decision might affect clinical practice around teratogen prescribing, abortion referrals, and perceived vulnerability to criminalization.

Methods: This study was designated as exempt by the University of Pittsburgh Institutional Review Board. QR codes to the survey were disseminated in November 2022: 1) at a plenary session about reproductive health at the American College of Rheumatology (ACR) national meeting; 2) via Twitter by study investigators during the ACR national meeting. Results were analyzed by descriptive statistics or chi-square tests, which compared responses by practice in abortion-restricted or protected states.

Results: Most respondents (N=152) identified as female (80.3%), practiced in academic settings (76.3%), and were in their early careers (fellows: 13.2%, < 10 years of independent practice: 47.4%). Approximately 47% of respondents practiced in abortion-restricted states. Half of respondents reported that one or more of their patients had ever become pregnant while using a teratogen (e.g., methotrexate, mycophenolate), and 34% had ever recommended abortion to a patient before Dobbs. Rheumatologists in abortion-restricted states were more comfortable referring a patient for abortion without fear of reprisal prior to Dobbs than post-Dobbs (83.1% and 34.8%, respectively; p< 0.001). Rheumatologists in abortion-restricted vs protected states were marginally more likely to report that they had changed or planned to change how often they prescribed methotrexate (13.0% vs 5.3%, p=0.146) and/or mycophenolate (8.7% vs 1.32%, p=0.05) to reproductive-age patients.

Conclusion: Our results suggest that rheumatologists’ prescribing patterns may change in the context of the nationwide abortion restriction, particularly in abortion-restricted states; reproductive-age females with rheumatic diseases may therefore have less access to evidence-based treatments such as mycophenolate and methotrexate [2-5]. Limitations of the current study include uncertain representativeness of the sample: the response rate cannot be calculated due to social media dissemination, and rheumatologists who had more interest in reproductive health issues may have been more likely to respond to the survey. Nonetheless, our findings underscore an urgent need for data to inform a concerted public health response that protects the health and well-being of females with rheumatic diseases.


Disclosures: M. Birru Talabi: None; B. Bermas: None; I. Blanco: None; A. Blazer: GlaxoSmithKlein(GSK), 2, Janssen, 2, Ucb, 2; M. Clowse: Exagen, 5, GlaxoSmithKlein(GSK), 2, 5, Immunovant, 5, UCB, 2, 5; C. Edens: None; L. Pierce: None; C. Wright: None; R. Ramsey-Goldman: Ampel Solutions, 2, Calabetta, 2, Exagen, 2, Immunocor, 6.

To cite this abstract in AMA style:

Birru Talabi M, Bermas B, Blanco I, Blazer A, Clowse M, Edens C, Pierce L, Wright C, Ramsey-Goldman R. The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-effects-of-post-dobbs-abortion-policy-on-rheumatology-clinical-practice-a-survey-of-rheumatologists/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effects-of-post-dobbs-abortion-policy-on-rheumatology-clinical-practice-a-survey-of-rheumatologists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology